Paragonix Technologies announced today that it launched the FDA-cleared PancreasPak organ preservation system.
PancreasPak becomes the first FDA-cleared device designed to protect and monitor donor pancreases during transportation to hit the market. Pre-orders begin today, June 27, with full availability earmarked for Sept. 1, 2024.
Waltham, Massachusetts-based Paragonix expects PancreasPak to “transform the pancreatic transplant field,” according to a news release. It utilizes the platform of the company’s SherpaPak cardiac transport system for tracking and controlling pancreatic transplantation.
The system establishes a controlled environment, digitally monitoring the pancreas at an optimal thermal range of 4-8°C for up to 21 hours. Paragonix says the pancreas, unlike other solid organs, is extremely delicate and vulnerable to damage during transport. Traditional methods like coolers and crushed ice expose the organ to harmful freezing temperatures.
“This milestone demonstrates our dedication to advancing the boundaries of organ transplantation excellence. We are honored to stand at the forefront of preservation and provide unparalleled support to countless patients in need of a heart, lung, liver, and now, pancreas,” said Dr. Lisa Anderson, CEO and President of Paragonix. “To be at the forefront and be the first company to provide pancreas preservation technology is a tremendous achievement and consistent with our commitment to service all transplant and donor patients.“
